Several exogenous GLP-1 receptor (GLP-1R) agonists have been approved as therapies for T2D, including exenatide, liraglutide, dulaglutide, and albiglutide [13]; liraglutide has also been approved for the treatment of obesity [14]. This evidence concerns the gene GLP1R and Obesity.